| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30078478 | HIV | ENSG00000072274.14 | protein_coding | TFRC | No | No | 7037 | G3V0E5 P02786 |
| TVIS30059251 | HIV | ENSG00000072274.14 | protein_coding | TFRC | No | No | 7037 | G3V0E5 P02786 |
| TVIS30059252 | HIV | ENSG00000072274.14 | protein_coding | TFRC | No | No | 7037 | G3V0E5 P02786 |
| TVIS30059253 | HIV | ENSG00000072274.14 | protein_coding | TFRC | No | No | 7037 | G3V0E5 P02786 |
| TVIS20011330 | HPV | ENSG00000072274.14 | protein_coding | TFRC | No | No | 7037 | G3V0E5 P02786 |
| TVIS20036753 | HPV | ENSG00000072274.14 | protein_coding | TFRC | No | No | 7037 | G3V0E5 P02786 |
| TVIS20056604 | HPV | ENSG00000072274.14 | protein_coding | TFRC | No | No | 7037 | G3V0E5 P02786 |
| TVIS20015301 | HPV | ENSG00000072274.14 | protein_coding | TFRC | No | No | 7037 | G3V0E5 P02786 |
| TVIS20038427 | HPV | ENSG00000072274.14 | protein_coding | TFRC | No | No | 7037 | G3V0E5 P02786 |
| TVIS44011303 | HTLV-1 | ENSG00000072274.14 | protein_coding | TFRC | No | No | 7037 | G3V0E5 P02786 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TFRC |
|---|---|
| DrugBank ID | DB01592 |
| Drug Name | Iron |
| Target ID | BE0008725 |
| UniProt ID | P02786 |
| Regulation Type | |
| PubMed IDs | 16564538 |
| Citations | Hemadi M, Ha-Duong NT, El Hage Chahine JM: The mechanism of iron release from the transferrin-receptor 1 adduct. J Mol Biol. 2006 May 12;358(4):1125-36. Epub 2006 Mar 13. |
| Groups | Approved |
| Direct Classification | Homogeneous transition metal compounds |
| SMILES | [Fe] |
| Pathways | Cerivastatin Action Pathway; Oxidation of Branched-Chain Fatty Acids; Simvastatin Action Pathway; Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2); Galactosemia III; Smith-Lemli-Opitz Syndrome (SLOS); Tyrosine Metabolism; Zellweger Syndrome; Hereditary Coproporphyria (HCP); Hypercholesterolemia; Glucose-6-phosphate Dehydrogenase Deficiency; Mevalonic Aciduria; Porphyrin Metabolism; Tryptophan Metabolism; Taurine and Hypotaurine Metabolism; Pentose Phosphate Pathway; Inositol Metabolism; Catecholamine Biosynthesis; Phenylketonuria; Vitamin A Deficiency; Congenital Erythropoietic Porphyria (CEP) or Gunther Disease; Cystinosis, Ocular Nonnephropathic; Pyrimidine Metabolism; Congenital Disorder of Glycosylation CDG-IId; Lovastatin Action Pathway; Nucleotide Sugars Metabolism; Aromatic L-Aminoacid Decarboxylase Deficiency; Cysteine Metabolism; Galactose Metabolism; The Oncogenic Action of Fumarate |
| PharmGKB | PA450087 |
| ChEMBL |
